S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
Log in
NASDAQ:CODX

Co-Diagnostics Stock Forecast, Price & News

$12.12
-0.49 (-3.89 %)
(As of 10/22/2020 04:48 PM ET)
Add
Compare
Today's Range
$11.90
Now: $12.12
$12.66
50-Day Range
$8.24
MA: $13.19
$15.17
52-Week Range
$0.85
Now: $12.12
$30.99
Volume1.11 million shs
Average Volume7.11 million shs
Market Capitalization$340.37 million
P/E Ratio67.33
Dividend YieldN/A
Beta-3.2
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Read More
Co-Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CODX
CUSIPN/A
Phone801-438-1036
Employees39

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$220,000.00
Book Value$0.10 per share

Profitability

Net Income$-6,200,000.00

Miscellaneous

Market Cap$340.37 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$12.12
-0.49 (-3.89 %)
(As of 10/22/2020 04:48 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

How has Co-Diagnostics' stock been impacted by COVID-19?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CODX shares have decreased by 8.1% and is now trading at $12.12.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Co-Diagnostics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Co-Diagnostics
.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Co-Diagnostics
.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its quarterly earnings data on Thursday, August, 13th. The company reported $0.43 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.59 by $0.16. The company had revenue of $24.04 million for the quarter, compared to the consensus estimate of $27 million. Co-Diagnostics had a net margin of 31.42% and a return on equity of 56.17%.
View Co-Diagnostics' earnings history
.

What price target have analysts set for CODX?

2 brokers have issued 1 year price objectives for Co-Diagnostics' shares. Their forecasts range from $30.00 to $33.00. On average, they anticipate Co-Diagnostics' stock price to reach $31.50 in the next year. This suggests a possible upside of 159.9% from the stock's current price.
View analysts' price targets for Co-Diagnostics
.

Are investors shorting Co-Diagnostics?

Co-Diagnostics saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 6,920,000 shares, a decline of 17.6% from the September 15th total of 8,400,000 shares. Based on an average daily trading volume, of 3,950,000 shares, the short-interest ratio is currently 1.8 days.
View Co-Diagnostics' Short Interest
.

Who are some of Co-Diagnostics' key competitors?

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Ibio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 67, Pay $295k)
  • Dr. Brent C. Satterfield, Co-Founder & Chief Science Officer (Age 43, Pay $237.5k)
  • Mr. Reed L. Benson, CFO & Sec. (Age 72, Pay $215k)
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional investors include Strategic Wealth Management Group LLC (0.05%). Company insiders that own Co-Diagnostics stock include Eugene Durenard and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics
.

Which major investors are selling Co-Diagnostics stock?

CODX stock was sold by a variety of institutional investors in the last quarter, including Strategic Wealth Management Group LLC. Company insiders that have sold Co-Diagnostics company stock in the last year include Eugene Durenard, and Richard S Serbin.
View insider buying and selling activity for Co-Diagnostics
.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $12.12.

How big of a company is Co-Diagnostics?

Co-Diagnostics has a market capitalization of $340.37 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 39 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at 801-438-1036 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.